Intact Investment Management Inc. Sells 12,500 Shares of CVS Health Corporation $CVS

Key Points

• Intact Investment Management sold 12,500 shares of CVS in Q4 (a 7.0% reduction), leaving 165,300 shares valued at about $13.12 million per its SEC filing.
• Wall Street consensus is a "Moderate Buy" with 20 Buy and 3 Hold ratings and a consensus price target of $95.05.
• CVS declared a quarterly dividend of $0.665 (annualized $2.66) for a 3.2% yield, though its dividend payout ratio is notably high at 192.75%.

Intact Investment Management Inc. lowered its position in CVS Health Corporation (NYSE:CVS - Free Report) by 7.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 165,300 shares of the pharmacy operator's stock after selling 12,500 shares during the period. Intact Investment Management Inc.'s holdings in CVS Health were worth $13,118,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd lifted its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after purchasing an additional 281 shares during the last quarter. Corundum Trust Company INC bought a new stake in CVS Health in the third quarter worth about $29,000. Ares Financial Consulting LLC bought a new stake in CVS Health in the fourth quarter worth about $29,000. GoalVest Advisory LLC bought a new stake in CVS Health in the fourth quarter worth about $32,000. Finally, Financial Consulate Inc. lifted its stake in CVS Health by 99.6% in the fourth quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator's stock worth $40,000 after purchasing an additional 249 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CVS. Leerink Partners reissued an "outperform" rating and issued a $98.00 price objective on shares of CVS Health in a research note on Thursday, March 5th. Piper Sandler decreased their price objective on shares of CVS Health from $101.00 to $99.00 and set an "overweight" rating for the company in a research note on Tuesday, March 31st. TD Cowen reaffirmed a "buy" rating on shares of CVS Health in a research report on Friday, March 13th. Wolfe Research reduced their target price on shares of CVS Health from $100.00 to $97.00 and set an "outperform" rating on the stock in a research report on Monday, March 2nd. Finally, Bank of America reduced their target price on shares of CVS Health from $100.00 to $95.00 and set a "buy" rating on the stock in a research report on Tuesday, January 27th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $95.05.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Regulatory tailwinds for Aetna and clearer PBM policy raised upside visibility for CVS’s Health Services and PBM businesses, boosting investor optimism about Medicare Advantage payments and reduced insulin‑pricing uncertainty. Regulatory Tailwinds Article
• Positive Sentiment: Operational efficiency gains from automation: WSJ reports on CVS’s new highly automated distribution center using robots to move millions of items with far fewer staff — a potential long‑term margin lever. Robotics/Operations Article
• Positive Sentiment: Competitive positioning: coverage notes CVS is pushing health‑services expansion while Walgreens pulls back, which could support share gains in higher‑margin care services. Competitive Positioning Article
• Neutral Sentiment: Earnings preview / analyst focus: Wall Street is parsing Q1 metrics (revenue, pharmacy trends and Health Services growth). Investors are waiting for the company’s March‑quarter results and management color before re‑rating shares. Earnings Countdown Article
• Negative Sentiment: Near‑term margin risk: earnings previews caution that benefits segment pressures and elevated costs could weigh on Q1 results, a key reason investors are cautious ahead of the print. Earnings Preview Article
• Negative Sentiment: Market dynamics and valuation: after a strong run-up, the stock’s rich near‑term multiples and lighter intraday volume can amplify down‑moves as investors lock in gains while awaiting Q1 clarity (contributing to today’s pullback).

CVS Health Stock Performance

Shares of NYSE:CVS opened at $82.12 on Monday. The firm has a market cap of $105.24 billion, a PE ratio of 59.51, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60. The firm's 50 day simple moving average is $76.32 and its 200-day simple moving average is $77.96. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.09. The business had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period last year, the company posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities analysts predict that CVS Health Corporation will post 7.14 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Thursday, April 23rd. CVS Health's dividend payout ratio (DPR) is presently 192.75%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.